Stoke Therapeutics, Inc.
STOK · Nasdaq · USD · Market cap $1.7B · 170 employees
Stoke Therapeutics, Inc.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price26.81 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.13)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $35.00 to $53.38, base estimate $43.00 (screen dated 2026-11-20).
- Trend Accumulation
- Insiders insiders sold, $16,509, latest filing 2026-10-02
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.13, read 2026-11-19
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Stoke Therapeutics, Inc. holds its Accumulation at $26.81. Consolidating, no directional conviction, held for 1 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 1 days |
| Price at the screen | $26.81 |
| Valuation | N/A trailing · -6.46 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.38 |
Five Screens: STOK's Results
FAIL. Revenue purity
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 0.72% | Below 33% | Pass |
| Interest-bearing cash | 25.39% | Below 33% | Pass |
| Receivables | 21.55% | Below 49% | Pass |
| Revenue purity | 7.46% | Below 5% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Stoke Therapeutics, clears the business-activity screen, and its debt is near-nil. Where it falls short is income purity: around 7% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when STOK's ethical verdict changes
Today STOK does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 38% discount to our $43.00 fair value, 5.90% revenue growth.
USD, 2026-11-20 screen. A 37.7% under base.
Street: 13 covering, consensus Strong Buy. Average target +60%.
| Forward P/E | -6.5x |
| EPS, trailing | -3.81 |
| EPS, forward | -4.09 |
| Revenue growth | +5.9%slow but positive growth |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -73.6%not currently earning a positive return on equity |
| FCF yield | -7.27% |
| Debt to equity | 0.55moderate, manageable leverage |
| Current ratio | 7.24comfortably covers its short-term bills |
| Beta | 1.38moves a little more than the market |
| Short interest, float | 0.17% |
| 52-week range | 22.05 - 40.22 |
| Market cap | $1.7B |
| Employees | 170 |
STOK-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
Since the last review it saw its composite score ease.
Since the last review it saw its composite score rise.
The framework has shifted from markdown to accumulation since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Stoke Therapeutics (STOK) Faces A Valuation Test Following Weaker Nine Month Results Yahoo Finance · 14d ago
- Stoke Therapeutics to Present at Upcoming Investor Conferences in November Yahoo Finance · 18d ago
- Stoke Therapeutics (STOK) Stock Price Faces Q3 Results Cash Burn Question Yahoo Finance · 21d ago
- Stoke (STOK) Q3 2026 Earnings Call Transcript Yahoo Finance · 22d ago
- Stoke Therapeutics, Inc. Q3 2026 Earnings Call Summary Yahoo Finance · 22d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Allan Jonathan | GC, Corp Sec | S - Sale | 627 | $16,509 |
| 2026-10-01 | Ticho Barry | Chief Medical Officer | S - Sale | 1,051 | $27,494 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $32.64 | -12.8% | · | $873 | -12.8% |
| 2 months | $34.33 | -17.0% | · | $830 | -17.0% |
| 3 months | $36.48 | -21.9% | · | $781 | -21.9% |
| 6 months | $33.09 | -13.9% | · | $861 | -13.9% |
| 1 year | $11.36 | +150.7% | · | $2,507 | +150.7% |
| 2 years | $14.89 | +91.3% | · | $1,913 | +91.3% |
| 3 years | $11.76 | +142.2% | · | $2,422 | +142.2% |
| 5 years | $37.71 | -24.5% | · | $755 | -24.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever STOK does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.